About Versant Ventures
Versant Ventures is a venture capital firm founded in 1999. It is primarily based out of Basel, Switzerland. As of Nov 2025, Versant Ventures is an active investor, having invested in 190 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Dayra Therapeutics Overall, Versant Ventures portfolio has seen 28 IPOs and 91 acquisitions including key companies like Jazz Pharmaceuticals, Insulet and Glaukos. A lot of funds co-invest with Versant Ventures, with names like New Enterprise Associates sharing a substantial percentage of its portfolio. Versant Ventures has team of 36 people including 14 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 8 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Versant Ventures' List of Top Investments
Versant Ventures has a portfolio of 190 companies. Their most notable investments are in SixPeaks Bio and Flexion Therapeutics.Their portfolio spans across United States, Switzerland, Canada and 11 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 11 other sectors, across stages such as Series A, Series B and 8 more. Here is the list of top investments by Versant Ventures:
Developer of novel biopharmaceutical medicines for unmet medical needs. It focuses on developing and delivering life-changing medications to patients with limited or no treatment options. The company's pipeline includes various therapeutic areas, and it supports its medicines with robust clinical trial programs and patient support resources. Research efforts prioritize patient needs, driving advancements in understanding and treating specific conditions. The company also engages in corporate giving and sustainability initiatives.
Key facts about Jazz Pharmaceuticals
- Founded Year: 2003
- Location: Dublin (Ireland)
- Annual Revenue: $500M - $1B as on Dec 31, 2020
- Stage: Public
- Total Funding till date: $265M
- Employee Count: 3,624 as on May 31, 2026
- Investors: Adams Street Partners, Thoma Bravo and 14 Others
- Latest Funding Round: Post IPO, Jul 07, 2009, $*****
- Highlight: Public
2. Insulet
Manufacturer of wearable, tubeless insulin delivery systems for diabetes management. The company develops and provides simple, connected devices for continuous insulin delivery. These devices offer an alternative to multiple daily injections. The company focuses on research and development to improve its technologies.
Key facts about Insulet
- Founded Year: 2000
- Location: Boston (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $120M
- Employee Count: 5,306 as on Jun 30, 2026
- Investors: Piper Jaffray, Deerfield and 13 Others
- Latest Funding Round: Post IPO, Jun 03, 2014, $*****
- Highlight: Public
3. Glaukos
Developer of implants to treat glaucoma. The company has developed the Micro-Invasive Glaucoma Surgery (MIGS) approach to treating glaucoma. Its product, the iStent is the first MIGS device that is implanted during cataract surgery to help lower eye pressure. It is also developing multiple micro-invasive, bioerodible, drug delivery platforms for the treatment of retinal disorders
Key facts about Glaukos
- Founded Year: 2001
- Location: Laguna Hills (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $118M
- Employee Count: 1,096 as on Jun 30, 2026
- Investors: Meritech, Versant Ventures and 9 Others
- Latest Funding Round: Post IPO, Jun 08, 2020, $*****
- Highlight: Public
4. Crinetics
Developer of therapies for the treatment of endocrine-related diseases and cancers. The company focuses on the development of drugs for endocrine disorders and cancers in the areas of neuroendocrinology, reproductive medicine, and women’s health. Its lead candidate is CRN04777, an oral SST5 agonist for hypoglycemia.
Key facts about Crinetics
- Founded Year: 2008
- Location: San Diego (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $104M
- Employee Count: 616 as on Jun 30, 2026
- Investors: Versant Ventures, Perceptive Advisors and 12 Others
- Latest Funding Round: Post IPO, Mar 01, 2024, $*****
- Highlight: Acquired
_1560516450043.png?format=webp&height=120&width=120){kind=logo}
5. Passage Bio
Developer of gene therapies for CNS rare diseases. The company has developed AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. Its lead programs are focused on GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease.
Key facts about Passage Bio
- Founded Year: 2017
- Location: Philadelphia (United States)
- Stage: Public
- Total Funding till date: $226M
- Employee Count: 51 as on Apr 30, 2026
- Investors: HTIF, Boxer Capital and 10 Others
- Latest Funding Round: Post IPO, Sep 09, 2021, $*****
- Highlight: Public
Versant Ventures' Year-on-Year Investment Trends
Versant Ventures has invested in 190 companies over the last 26 years, with an average of 6 new investments annually in the last 10 years. In 2025, it made 5 investments. Its most recent first time investment was in Dayra Therapeutics and most recent follow-on round was in 858 Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 5 | 0 | 5 |
2024 | 4 | 4 | 8 |
2023 | 4 | 4 | 8 |
2022 | 3 | 3 | 6 |
2021 | 7 | 9 | 16 |
2020 | 8 | 7 | 15 |
2019 | 4 | 9 | 13 |
2018 | 12 | 7 | 19 |
2017 | 8 | 5 | 13 |
Versant Ventures' Investments by Stage
Versant Ventures has made 81 investments in Series A stage with an average round size of $41M, 41 investments in Series B stage with an average round size of $22.5M and 28 investments in Series C stage with an average round size of $43M.Stage of entry | No. of Investments |
|---|---|
Series A | 81 |
Series B | 41 |
Series C | 28 |
Series D | 5 |
Post IPO | 4 |
Others | 12 |
Note: We have considered here, only first round of investments
Versant Ventures' Investments by Sector
Versant Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Sustainability Tech. Notably, it has invested in 154 Tech companies, 152 Enterprise (B2B) companies, 43 Software companies and at least 20 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 143 |
High Tech | 26 |
Enterprise Applications | 24 |
HealthTech | 15 |
Sustainability Tech | 14 |
Others | 27 |
Note: We have considered here, only first round of investments
Versant Ventures' Investments by Geography
Versant Ventures has made most investments in United States (145), followed by Switzerland where it has made 13 investments.Country | No. of Investments |
|---|---|
United States | 145 |
Switzerland | 13 |
Canada | 4 |
France | 2 |
China | 1 |
Others | 8 |
Note: We have considered here, only first round of investments
Versant Ventures' recent investments
Versant Ventures has not made any investment in 2026 so far.Here are the most recent investments by Versant Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 24, 2025 | United States | Series C | 4056 | ||
Sep 16, 2025 | United States | Series A | 2782 | ||
Apr 24, 2025 | Switzerland | Series A | 8300 | ||
Jan 28, 2025 | United States | Series A | 6664 | [+2] | |
Jan 09, 2025 | United States | Series A | 7689 | [+3] |
IPOs and Publicly Listed companies in Versant Ventures' Portfolio
28 of Versant Ventures' portfolio companies have become public. Minerva Surgical got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2021 at marketcap of $343M and Jade Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Versant Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 22, 2021 | - | - | 2883 | |
Jul 02, 2021 | Oct 23, 2024 | Post IPO | 6230 | |
Jun 25, 2021 | Jun 17, 2021 | Series A | 2969 | |
Jun 24, 2021 | May 26, 2020 | Series A | 3214 | |
Jun 18, 2021 | Jul 01, 2019 | Series C | 3204 |
Acquired companies in Versant Ventures' Portfolio
91 companies from Versant Ventures' portfolio have been acquired. The most recent acquisition was Crinetics in Jul 2026 by Vertex Pharmaceuticals for $*****.Here are Versant Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 06, 2026 | Nov 13, 2015 | Series A | 9608 | |
Jun 08, 2026 | Dec 18, 2023 | Series A | 4717 | |
Feb 24, 2026 | May 28, 2015 | Series C | 1389 | |
Nov 14, 2025 | Jun 22, 2017 | Series A | 5163 | |
Oct 24, 2025 | May 18, 2016 | Post IPO | 9079 |
Team profile of Versant Ventures
Versant Ventures has a team of 36 members including 14 Partners, 9 Venture Partners and 4 Principals located in United States, Switzerland and 2 more locations. Versant Ventures' team sits on the board of 2 companies.Here is a list of top team members in Versant Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | Arlesheim | - | - | |
Partner | San Francisco | - | - | |
Partner | Minneapolis | - | - | |
Partner | New York City | - | ||
Partner | Palo Alto | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | San Francisco | - | - |
Co-investors of Versant Ventures
Over the past 26 years, 675 investors have co-invested in Versant Ventures's portfolio companies. This includes funds and angels.
- Invested before Versant Ventures: HHS, Venrock and 93 others have invested in rounds before Versant Ventures. There are 8 companies where HHS has invested before Versant Ventures and 3 companies where Venrock has invested before Versant Ventures.
- Top Co-investors of Versant Ventures: 242 investors entered a company along with Versant Ventures. These include investors like New Enterprise Associates (14 companies).
- Invested after Versant Ventures: A total of 338 investors have invested in Versant Ventures's portfolio after their investments. Top Investors include Orbimed (12 companies), RA Capital Management (10 companies) and SVB (9 companies).
Recent News related to Versant Ventures
•
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnershipintelligence360•Dec 18, 2025•Versant Ventures, Biogen
•
Dayra Therapeutics Secures Over $70M in Committed FundingFinSMEs•Nov 24, 2025•Biogen, Versant Ventures, Dayra Therapeutics
•
•
Gate Bioscience Announces $65 Million Series B Financing to Advance Oral Molecular Gate MedicinesBenzinga•Nov 13, 2025•Gate Bioscience, Lilly, Forbion, Google Ventures and 3 others
•
AstraZeneca acquires SixPeaks Bio to advance obesity treatmentsSilicon Canals•Nov 07, 2025•AstraZeneca, , Versant Ventures, Goodwin
•
•
•
•
Helicore Biopharma’s $65 Million Series A Financing RoundGlobal Legal Chronicle•Feb 24, 2025•Orbimed, Versant Ventures, Helicore Biopharma
•
U.S. Capital Wealth Advisors LLC Invests $7.70 Million in Welltower Inc. (NYSE:WELL)MarketBeat•Feb 02, 2025•US Capital Advisors, Welltower, Laurel Wealth Advisors, Fortitude Re and 3 others
